Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
With the approval by the European Commission in November 2012.....
Volgen
02elf.net/gesundheit/krankenkassen-so... Health insurance companies should not pay for low innovativeness of medicines In May 2015, the Federal Joint Committee (G-BA) has fallen into a situation where he drug Glybera (active ingredient: Alipogentiparvovec, therapy costs about one million euros) first had to certify an additional benefit by law, although the risk-benefit ratio of the European Medicines Agency can not be evaluated yet. Medicines like Glybera to treat rare diseases (orphan drugs) are used to get, by law automatically added value attests, if it does not exceed the sales limit of 50 million euros a year. That makes no sense professionally. Even if a drug has been developed for the treatment of a rare disease, it should only be used if it has a real added value for the patienttinyurl.com/q5nwkg4
Der PZ-Innovationspreis geht in diesem Jahr an Takeda Pharma für den monoklonalen Antikörper Vedolizumab (Entyvio®). Der neue Arzneistoff wird bei chronisch-entzündlichen Darmerkrankungen eingesetzt. Im Rahmen des Fortbildungskongresses Pharmacon in Meran überreichte Sven Siebenand, stellvertretender Chefredakteur der Pharmazeutischen Zeitung, den Preis Apothekerin Cornelia Zanetti, Leiterin des Geschäftsbereiches chronisch-entzündliche Darmerkrankungen bei Takeda Pharma. Rund 20 neue Arzneistoffe aus dem Jahr 2014 standen der achtköpfigen Jury – bestehend aus Pharmazieprofessoren und Offizinapothekern – zur Auswahl. Zudem hatten alle Apothekenmitarbeiter die Möglichkeit, sich auf der Facebook-Seite der PZ an der Wahl des Siegers zu beteiligen. «Einige der neuen Wirkstoffe sind als Sprunginnovation einzustufen und wären ebenfalls würdige Preisträger gewesen», betonte Siebenand. Vedolizumab überzeugte die Jury, weil der Arzneistoff seinen antientzündlichen Effekt selektiv im Darm entwickelt. Positiv hervorzuheben sei, dass mit Vedolizumab nach langer Zeit wieder ein Vertreter aus der Substanzklasse der Integrin-Antagonisten auf den Markt gekommen ist. Dieses Wirkprinzip ist bei der Behandlung von chronisch-entzündlichen Darmerkrankungen wie Morbus Crohn und Colitis ulcerosa vollkommen neu.Erstmalig wurde in Meran auch ein PZ-Innovations-Sonderpreis verliehen. Dieser ging an das erste in Europa zugelassene Gentherapeutikum: Alipogentiparvovec (Glybera® von Chiesi). Dass es gelungen sei, einen ersten Wirkstoff dieser Therapieform zur Marktreife zu führen, war für die Jury der ausschlaggebende Grund für die Auszeichnung. Im Rahmen der Zulassung mussten dabei auch die Bedingungen für die Zulassung eines Gentherapeutikums festgelegt werden. «Damit ist wertvolle Vorarbeit für weitere potenzielle Gentherapeutika geleistet worden, die nun eventuell schneller auf den Markt gelangen können», sagte Siebenand. www.pharmazeutische-zeitung.de/index.... tinyurl.com/noj3qeh
Moest even mijn Duits opvijzelen maar het lijkt positief nieuws.
Poolse radio: Grzegorz Jasinski: The subject of our conversation are the latest treatments, very modern, but also very costly and sometimes risky.I would like to start by asking about Glybere, a treatment for hereditary lipoprotein lipase deficiency (LPLD), which surprised public opinion to its price tag in excess of one million euros.Is it already the new medicine, whether it is a step towards a new medicine, or it may lower, which will concern only certain diseases, but the whole of medicine will not change? Prof.Seppo Yla-Herttuala: Glybera is a tip of the iceberg, the first such drug, approved in the EU and it is clear that the millionth price is far too high.It can not be justified differently in that worldwide use of this therapy is at most 100 to 150 people.But I am convinced that if there will be a new type of real drugs when they are related to more common diseases, their price will reach at most a fraction of the current price Glybery. But how quickly can we expect next from this type of medicine?Is now the process will be faster if we will have to continue to wait very long? Prof.Seppo Yla-Herttuala: At the moment we have two very promising, close to the approval of gene preparations.One, USA, has anti-tumor activity, the other is to act against a strong immune deficiency states, it is one of the so-called rare diseases.Work on the preparation are carried out in Europe, precisely in Milan. Meer via:translate.google.nl/translate?hl=nl&a... Seppo Yla-Herttuala van:www.nature.com/mt/journal/v20/n3/pdf/... www.nature.com/mt/journal/v20/n10/pdf... www.nature.com/mt/journal/v23/n2/pdf/... www.eurekalert.org/pub_releases/2013-...
Since AmpliPhi entered into an asset purchase and amended license agreement with Celladon in June 2012 to provide for an additional up-front cash payment in return for reducing its royalties to 1.5%, the revenue stream from Mydicar would not have been that significant. This is not the case however for Glybera, for which the company would receive mid-single-digit royalties from uniQure (NASDAQ:QURE) (which acquired the drug from Amsterdam Molecular Therapeutics B.V.) should it be approved. These royalties could add up for a drug that's projected to do up to $300 Mil+ a year in sales with an astronomical price tag of over Euro 1.1 Mil per patient. The recent determination by the European Medicines Agency (EMA) that the drug lacks efficacy (see First EU-Authorized Gene Therapy Hits Snag, Benefit Assessment Delayed in Germany as EMA Reviews New Report) puts future European royalties from Glybera in doubt, lowers the chances of FDA approval, and could leave the company with only the pre-clinical bacteriophage assets underpinning the value of the stock.seekingalpha.com/article/3365075-ampl... Btw: commentaar @schrijver art.is reeds verzonden.
$XENE Earnings Call Transcript: Glybera $QURE tinyurl.com/njk85qc Finally I will provide a very quick update on Glybera this is the first product whose active ingredient was derived from our platform to receive commercial approval, it's currently the only gene therapy product to receive approval in Europe. Glybera specifically indicated for the treatment of a subset of adult patients diagnosed with the orphan lipid disorder known as Lipoprotein lipase deficiency or LPLD, confirmed much by testing, these patients suffered from severe multiple episodes of pancreatitis despite dietary fat restriction. Glyberawas developed by our licensee uniQure Biopharma being commercialized by uniQure's partner Chiesi, although we are not giving specific guidance about Glybera, we do understand that Chiesi has submitted price and reimbursement dossiers in key European countries to make Glyberia accessible to patients who will provide additional information as we receive it.
Gentherapie levert pionierwerk voor veel ziekteswww.zonmw.nl/?id=53&tx_zonmwdata_...
Mention Glybera: FDA, verslag uit 2014. (Via screenshot, geen pagina nr.) “Complex Issues in Rare Diseases Drug Development” PUBLIC AGENDA- DAY2 January 7, 2014 FDA White Oak Campus (Silver Spring, MD) www.fda.gov/downloads/drugs/newsevent...
twitter.com/johncfierce/status/636928... UniQure mulls options for $1M gene therapy after FDA demands extra trial The path to bringing a gene therapy to market in the U.S. just got a little rockier. Having expected to swing for approval in the U.S. on the basis of one pivotal trial, uniQure ($QURE) has now learnt the FDA is demanding another clinical study. Glybera appeared to have a clear path forward as recently as June. At that time, uniQure said the plan was to initiate a clinical trial in 2016 and use the data in a filing with the FDA. However, the FDA has scuttled the plan by telling uniQure it wants to see data from another clinical trial in the BLA filing. What happens now is unclear. UniQure is still planning to start up a U.S.-based trial early next year to meet the post-approval requirements of its European marketing nod, but is "assessing its options" for pursuing approval from the FDA. Investors reacted badly to the setback, sending shares in uniQure down by as much as 14% in premarket trading. With a big-ticket collaboration with Bristol-Myers Squibb ($BMY) to its name, uniQure is far from being reliant on Glybera. But the treatment for the genetic disease lipoprotein lipase deficiency (LPLD) is both uniQure's best near-term shot at getting a product on the market and a possible harbinger for what is to come for the gene therapies that are following it down the R&D pipeline. As the advanced party in the gene therapy field, Amsterdam, the Netherlands-based uniQure is used to setbacks. Glybera won approval in Europe in 2012 but a regulatory request for 6-year follow-up data held back its introduction. The recurring question throughout Glybera's slow crawl through the regulatory machinery has been how to assess the safety and efficacy of a new type of product that treats such a tiny patient population. For the FDA, the answer appears to lie in more data. For uniQure and its €1.1 million ($1.2 million) gene therapy, the upshot is more delays and uncertainty.
If $QURE is confident in their technology, isn’t Glybera registration in the US the type of low hanging fruit you’d like to pick right away?twitter.com/ogut_ozgur/status/6370453...
EMA PRAC agenda meeting 07-10 Sept.2015 tinyurl.com/ppytywx
Italy expects authorization AIFA: Rome, Palermo, Padua tinyurl.com/pxlg4ql
EMA PRAC. Glybera Publ. 23/09/2015 www.ema.europa.eu/docs/en_GB/document... EMA:Committee for Advanced Therapies (CAT) Glybera Publ.25/09/2015www.ema.europa.eu/docs/en_GB/document...
Hallo flosz, wat ga je doen, na dit alles gelezen te hebben?
Een curry madras maken met verse naan en what's going On uit de speaker..... m.youtube.com/watch?v=pDQ_EA5DJqI
For $QURE fans: I just looked up Glybera price in German real world setting, €53.78k/vial, adj to weight ~€1.34M. twitter.com/med__twi/status/649544915...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
867,27
+0,22%
EUR/USD
1,0683
+0,11%
FTSE 100
7.847,99
0,00%
Germany40^
17.819,80
+0,28%
Gold spot
2.380,34
+0,82%
NY-Nasdaq Composite
15.683,37
-1,15%
Stijgers
Dalers